Early-Stage Innovative Technology Development for Basic and Clinical Cancer Research (R61 Clinical Trial Not Allowed)
Awards up to $150,000 per recipient for business, nonprofit, other legal entity, public agency, tribal government, closing Nov 10, 2026.
In one sentence
Early-Stage Innovative Technology Development for Basic and Clinical Cancer Research (R61 Clinical Trial Not Allowed) awards up to $150,000 per recipient, open to business, nonprofit, other legal entity, public agency, tribal government, closing Nov 10, 2026.
- Program pool (total)
- $5,100,000Total across all awards in this programme. Not an amount any single applicant can receive.
- Award ceiling (per project)
- $150,000
- Award floor
- Not confirmed
- Typical award
- Not confirmed
- Deadline
- Nov 10, 2026
- Deadline type
- Fixed date
- Opens
- Jun 3, 2026
- Status
- Open
- Eligible entities
- Business · Nonprofit · Other Legal Entity · Public Agency · Tribal Government
- Geography
- Not stated
- Matching funds
- Not confirmed
- Disbursement
- Not confirmed
- Application effort
- Not confirmed
- Use of funds
- develop innovative technologies offering new capabilities for the molecular or cellular characterization of cancer · improved handling and quality control of biospecimens for basic, clinical, or epidemiological cancer research
- Currency
- USD
How much money is available?
Two different figures govern a programme and they are not interchangeable. The programme pool is what the funder has allocated across every award it will make this cycle. The award ceiling is the most one applicant can be granted.
Who can apply?
Not confirmed
Source field: applicant size limitRefer to Section III. Eligibility Information in the NOFO for additional information on eligibility.Foreign Organizations/International Collaborations:Non-domestic (non-U.S.) Entities (Foreign Organizations) are eligible to apply.Non-domestic (non-U.S.) components of U.S. Organizations are eligible to apply.Foreign components, as defined in the NIH Grants Policy Statement, are allowed.
We store the structured fields above. Clause-by-clause text from the guidelines is not connected for this record.When does it close?
What can the money be used for?
2 categorysThe source’s own spending categories, and what is not parsed.
These categories come from the source's own classification. A line-item cost table, where the programme publishes one, lives in the guidelines and is not parsed for this record.
Common questions
5 questionsEvery answer is a stored field from this record. Questions the source did not answer are not asked.
- How much can one applicant receive?
- Up to $150,000 per recipient.
- How much funding is available in total?
- $5,100,000 across the whole programme. This is the total the funder has allocated, not an amount any single applicant can receive.
- When is the application deadline?
- Nov 10, 2026.
- Who is eligible to apply?
- Business, Nonprofit, Other Legal Entity, Public Agency, Tribal Government.
- What can the funding be used for?
- develop innovative technologies offering new capabilities for the molecular or cellular characterization of cancer, improved handling and quality control of biospecimens for basic, clinical, or epidemiological cancer research, as classified by the source.
AI summary of the source text
Optional. Every core field on this record is already above, free and complete.
AI summary of the source text
Studio reads this record’s stored eligibility and materials text and breaks it into separate points, each quoting the exact words it came from. It never writes application prose, never guesses at a field the source did not state, and never estimates anyone’s chances.
Included with Studio
Sign inThe official page governs. If the source and this record disagree, the source is correct — programmes change their terms between our checks, so confirm every figure above before you apply.